Skip to main content
News Release | Rankings & Recognitions

Fasken Talent Recognized in Lexpert’s Top 10 Business Decisions of 2025/2026

Fasken
Reading Time 3 minute read
Share
  • LinkedIn

Overview

The Firm’s Litigation and Dispute Resolution and Life Sciences groups were acknowledged for their contribution to two of the most significant business decisions of 2025/2026.

Toronto (Canada) – Fasken was recognized across Canada for our contribution to two of the most significant business decisions of 2025/2026 in this year’s edition of Lexpert’s Top 10 Business Decisions. The list is based on an assessment of the most significant Canadian legal cases with decisions released between Oct. 1, 2025, and Sept. 30, 2026.

Of the top ten cases recognized, the Firm advised on the following:

In Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, the Fasken team was led by Julie Desrosiers and Eliane Elbogen who acted as co-counsel to Janssen Inc. and Janssen Pharmaceutica N.V. in defence of a challenge to its patent for the INVEGA SUSTENNA® dosing regimen. The case considered whether specific drug dosing regimens can be protected by patents in Canada. Janssen is a pharmaceutical company that develops medications and treatments across a range of medical areas.

In Angus A2A GP Inc v Alvarez & Marsal Canada Inc, 2026 ABCA 156, the Fasken team was led by Robyn Gurofsky and Kaitlyn Wong who acted as representative counsel to Michael Edwards, Paul Lauzon, Isabelle Brousseau, Pat Wedlund, Brian Richards and Canadian Investors in insolvency proceedings involving the A2A Group. The case considered whether investors could initiate proceedings under Canada’s Companies’ Creditors Arrangement Act (CCAA). The Alberta Court of Appeal upheld the proceedings and confirmed that investors can do so in appropriate circumstances.

Fasken’s Insolvency & Restructuring team, is one of the largest and most highly regarded in Canada, with experienced practitioners across the country’s major business centers. The team advises clients on restructuring businesses and debt obligations, recovering debt and enforcing security, managing liquidity and financial distress, developing forward-looking strategies to manage financial and operational risk, and acquiring or selling distressed businesses and assets. Its lawyers are regularly involved in complex and high-profile restructurings and insolvency proceedings across Canada and bring extensive experience to cross-border matters. With a practical and strategic approach, the team helps clients preserve and recover value while identifying effective solutions in complex and evolving circumstances.

Fasken’s Life Sciences group is a leading force in Canada. They are called upon at every stage of a clients’ product life cycle, from early stages of development and commercialization through to consumer use. The team includes lawyers with advance degrees in pharmaceutical sciences, clinical pharmacology, toxicology and genetics with a strong network of life sciences experts in 47 countries across the globe. They are committed to leadership in life sciences law, wrote the leading guide to legal and regulatory regimes governing the manufacture and sale of drugs, medical devices and cosmetics in Canada, and give frequent presentations to client organizations and associations. The group works collaboratively to solve significant legal issues that demand creative approaches and robust strategic advocacy. Renowned for their pragmatic and results-oriented advice, they are trusted to guide clients to successful outcomes. 

About Fasken

As a premier law firm with over 900 lawyers worldwide, Fasken is where excellence meets expertise. We are dedicated to shaping the future our clients want, precisely when it matters most. For more information, visit fasken.com.

Media Contact

  • François Richard
François Richard Media Relations Manager +1 514 871 5987
+1 438 367 4766